NCR3LG1 and melanoma: In the presence of the BRAFi vemurafenib, BRAFV600E-mutant melanoma cells displayed strong downregulation of the NKAR ligands MICA, CD155, and B7-H6 [94], which may result in melanoma cell resistance towards NK cell cytotoxicity as a direct byproduct of acquired BRAFi resistance.